Covered recipient · General Payments record
LUIS CHAVEZ
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$4,033.95
- Reported across 81 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,233.94 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $616.89 | 5 |
| Novo Nordisk AS | $262.85 | 7 |
| Medtronic, Inc. | $150.76 | 1 |
| BAXTER HEALTHCARE | $103.27 | 1 |
| Lilly USA, LLC | $65.36 | 3 |
| CeQur Corporation | $34.81 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $133.07 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111547138 | CMS |
| Amgen Inc. | $93.86 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111547142 | CMS |
| Amgen Inc. | $149.76 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111547136 | CMS |
| Amgen Inc. | $125.00 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111547140 | CMS |
| Amgen Inc. | $115.20 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111547144 | CMS |
| Baxter Healthcare | $103.27 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120650927 | CMS |
| CeQur Corporation | $34.81 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126846316 | CMS |
| Lilly USA, LLC | $23.64 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135139554 | CMS |
| Lilly USA, LLC | $23.22 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135097160 | CMS |
| Lilly USA, LLC | $18.50 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135142849 | CMS |
| Medtronic, Inc. | $150.76 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119414278 | CMS |
| Novo Nordisk Inc | $2.92 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096919420 | CMS |
| Novo Nordisk Inc | $17.73 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096693207 | CMS |
| Novo Nordisk Inc | $23.47 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096924676 | CMS |
| Novo Nordisk Inc | $13.03 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096941142 | CMS |
| Novo Nordisk Inc | $59.09 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096696856 | CMS |
| Novo Nordisk Inc | $125.00 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096943295 | CMS |
| Novo Nordisk Inc | $21.61 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096886503 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.